seek and you will find
- …
seek and you will find
- …
SeekIn envisions that by leading a new norm for cancer early detection the clinical outcome of mid-/late-stage cancer patients can be reversed and the cancer mortality rate can be reduced by 15%.
About Us
SeekIn Inc is a biotech company founded in early 2018, focusing on blood-based pan cancer early detection utilizing next-generation sequencing and artificial intelligence. Since founded, SeekIn has been committed to providing cutting-edge and cost-effective solutions for cancer early detection, postoperative recurrence monitoring, and treatment response evaluation. SeekIn also developed novel molecular tests for leukemia patients. With its proprietary technical advances, SeekIn has launched a number of research and clinical studies in collaboration with top-tier hospitals in Japan, EU and China.
The management team of SeekIn consists of experts with insightful and complementary experiences in R&D, clinical lab management, business operations, corporate finance, and product commercialization.
In October 2020,Dr. Mao was invited to give a talk on TEDxTheBoud's annual meeting again (TEDxTheBund talk in 2018). As TED's vision is the power of ideas to change the world, his wish is to use early detection to control cancer, the emperor of all maladies.
I hope that with all our efforts today, when we identify a positive case, the person will say to me, "Dr. Mao, no worries. I just have cancer".
——— Mao Mao
Dr. Mao's TEDxTheBund talk in 2020
Our Solution
multiplex, stepwise, cost-effective blood-based cancer screening
A NGS test to capture cancer genetic features in plasma
To calculate cancer risk score
Non-invasive blood based screening method,10ml blood
Newsroom
17. August 2024 · Press Releases24. Mai 2024 · Press Releases19. April 2024 · Press Releases10. April 2024 · Media Resources9. April 2024 · Press Releases12. Januar 2024 · Media ResourcesMore Posts
Contact Us
10320 Camino Santa Fe, Suite G
San Diego, CA 92121
United States
info@
© 2024 SeekIn Inc.
All Rights Reserved.